Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
LXRX | US
-0.18
-8.70%
Healthcare
Biotechnology
30/06/2024
02/06/2026
1.89
2.09
2.09
1.88
Lexicon Pharmaceuticals Inc. a biopharmaceutical company focuses on the discovery development and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211 which is in Phase II clinical development for the treatment of neuropathic pain and LX2761 which is in Phase I clinical development for gastrointestinal tract. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech Inc. The company was incorporated in 1995 and is headquartered in The Woodlands Texas.
View LessStrong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
68.6%1 month
105.9%3 months
75.5%6 months
84.0%-
-
3.03
0.44
0.28
-2.58
142.11
-0.14
-196.47M
683.22M
683.22M
-
-3.36K
-63.40
419.60
-94.81
11.39
16.55
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.41
Range1M
1.01
Range3M
1.08
Rel. volume
0.98
Price X volume
5.94M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Corvus Pharmaceuticals Inc | CRVS | Biotechnology | 11.69 | 731.22M | -3.23% | n/a | 1.37% |
| Absci Corporation Common Stock | ABSI | Biotechnology | 6.35 | 721.08M | -2.61% | n/a | 6.02% |
| Sana Biotechnology Inc. Common Stock | SANA | Biotechnology | 3.24 | 720.79M | 0.93% | n/a | 29.02% |
| Janux Therapeutics Inc. Common Stock | JANX | Biotechnology | 13.78 | 718.83M | -4.37% | n/a | 3.62% |
| MeiraGTx Holdings plc | MGTX | Biotechnology | 9.24 | 713.18M | -5.71% | n/a | 109.40% |
| Eton Pharmaceuticals Inc | ETON | Biotechnology | 27.4 | 707.91M | -4.46% | n/a | 36.23% |
| Geron Corporation | GERN | Biotechnology | 1.17 | 705.27M | -3.31% | n/a | 28.38% |
| Kura Oncology Inc | KURA | Biotechnology | 8.97 | 687.41M | -0.72% | n/a | 3.59% |
| Unicycive Therapeutics Inc. Common Stock | UNCY | Biotechnology | 7.23 | 682.20M | -4.87% | n/a | -315.38% |
| X4 Pharmaceuticals Inc | XFOR | Biotechnology | 4.04 | 680.74M | -1.70% | 4.00 | 82.82% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Janus International Group Inc. | JBI | Building Products & Equipment | 5.12 | 744.05M | -2.48% | 11.62 | 116.21% |
| Latham Group Inc. | SWIM | Building Products & Equipment | 5.32 | 614.87M | 0.00% | 65.18 | 77.00% |
| Malibu Boats Inc | MBUU | Recreational Vehicles | 27.52 | 550.14M | -1.75% | n/a | 1.50% |
| Ennis Inc | EBF | Building Products & Equipment | 20.73 | 539.06M | 0.63% | 13.28 | 2.28% |
| MCBC Holdings Inc | MCFT | Recreational Vehicles | 23.21 | 385.46M | -0.04% | 34.27 | 26.82% |
| ACCO Brands Corporation | ACCO | Building Products & Equipment | 3.88 | 371.70M | -0.77% | n/a | 174.23% |
| Camping World Holdings Inc | CWH | Recreational Vehicles | 7.44 | 335.76M | -1.06% | n/a | 3644.76% |
| Urban One Inc | UONEK | Broadcasting - Radio | 4.7 | 249.14M | -10.36% | n/a | 268.43% |
| CPI Card Group Inc | PMTS | Building Products & Equipment | 16.74 | 186.78M | -0.42% | 15.61 | -621.78% |
| ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 11.36 | 182.41M | 2.53% | n/a | 286.96% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -2.58 | - | Cheaper |
| Ent. to Revenue | 142.11 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.03 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 75.52 | - | Par |
| Debt to Equity | 0.44 | -1.23 | Expensive |
| Debt to Assets | 0.28 | 0.25 | Par |
| Market Cap | 683.22M | - | Emerging |